Atypical fractures and molecular environment: What do we know?

Injury. 2018 Nov;49(11):1953-1958. doi: 10.1016/j.injury.2018.10.008.

Authors

Abdel R Elniel¹, Peter V Giannoudis²

Affiliations

¹ Academic Department of Trauma and Orthopaedics, Leeds Teaching Hospitals, School of Medicine, University of Leeds, Leeds, United Kingdom.
² Academic Department of Trauma and Orthopaedics, Leeds Teaching Hospitals, School of Medicine, University of Leeds, Leeds, United Kingdom; NIHR Leeds Biomedical Research Center, Chapel Allerton Hospital, Leeds, UK. Electronic address: pgiannoudi@aol.com.

PMID: 30366688
DOI: 10.1016/j.injury.2018.10.008

No abstract available

Publication types

Editorial

MeSH terms

Bone Density Conservation Agents / administration & dosage
Bone Density Conservation Agents / adverse effects*
Diphosphonates / administration & dosage
Diphosphonates / adverse effects*
Dose-Response Relationship, Drug
Fracture Healing / physiology
Fractures, Bone / chemically induced*
Humans
Osteoporosis / drug therapy*
Risk Factors

Substances

Bone Density Conservation Agents
Diphosphonates